The annual distribution of AE reports showed a trend of increasing first and then decreasing, and the distribution of years reported by AEs with severe outcomes showed similar characteristics.
← all excerpts
Post-marketing safety surveillance of dalfampridine for multiple sclerosis using FDA adverse event reporting system.
1
—
—